Impressive regression of primary liver cancer after treatment with sirolimus

Acta Oncologica

Volumn 44, Issue 5, 2005, Pages 496-

  Rizell, Magnus ^a   Cahlin, Christian ^a   Friman, Styrbjörn ^a   Hafström, Lo ^a   Lönn, Lars ^a   Olausson, Michael ^a   Lindner, Per ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; RAPAMYCIN;

ADULT; BODY MASS; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; HEPATITIS C; HUMAN; LETTER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM REGRESSION, SPONTANEOUS; SIROLIMUS;

EID: 23944493317     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510044610     Document Type: Letter

References (5)

1. Wong LL. Current status of liver transplantation for hepatocellular cancer. Am J Surg 2002;183:309-16.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17.
3. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-75.
4. Xu X, Sakon M, Nagano H. Akt2 expression correlates with prognosis of human hepatocellulär carcinoma. Oncol Rep 2004;11:25-32.
5. Rizell M, Lindner P. Inhibition of mTOR suppresses experimental Liver Tumours. Anticancer Research 2005;25:789-94.